Evidence map›Paper›PMID 38724654›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2024

A head-to-head comparison of [

Jieling Zheng, Guochang Wang, Qian Ru, Yun Yang, Li Su, Wenlong Lv, Chunlin Ke, Peirong Wang, Xiaohui Liu, Li Zhang and 2 more

Erratum issuedAbstract readComparative StudyClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Jieling ZhengDepartment of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.
Guochang WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.
Qian RuDepartment of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
Yun YangDepartment of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.
Li SuDepartment of Radiotherapy, the First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.
Wenlong LvDepartment of Radiotherapy, the First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.
Chunlin KeDepartment of Radiotherapy, the First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.
Peirong WangDepartment of Radiotherapy, the First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.
Xiaohui LiuDepartment of Radiotherapy, the First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China.
Li ZhangDepartment of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
Feng LiuDepartment of Radiotherapy, the First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China. fjmu@sina.cn.
Weibing MiaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, Fujian Province, China. miaoweibing@126.com.ORCID 0000-0002-0058-4953

Funding

Fujian Provincial Health Technology Project 2022QNA032Joint Funds for the Innovation of Science and Technology Fujian Province No.2021Y9134Natural Science Foundation of Fujian Province No.2023J01564
6 · The paper itself

Abstract

purposeWe aimed to compare the staging efficiency of [

methodsThirty-nine patients with pathologically confirmed NPC were enrolled in this prospective study. Each patient underwent paired [

resultsFor treatment-naïve patients, [

conclusion[

Indexed as

Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsOrganometallic CompoundsPositron Emission Tomography Computed TomographyAdultAgedFemaleGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNeoplasm StagingProspective StudiesRadiopharmaceuticalsgallium 68 PSMA-11gallium Ga 68 dotatateGallium IsotopesGallium RadioisotopesOrganometallic CompoundsRadiopharmaceuticals[68Ga]Ga-DOTATATE. [68Ga]Ga-FAPI. Nasopharyngeal carcinoma. TNM stage

Identifiers

PMID38724654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.